PF-04605412
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Non-Hematologic Malignancies
Conditions
Advanced Non-Hematologic Malignancies
Trial Timeline
Sep 1, 2009 → Jan 1, 2013
NCT ID
NCT00915278About PF-04605412
PF-04605412 is a phase 1 stage product being developed by Pfizer for Advanced Non-Hematologic Malignancies. The current trial status is terminated. This product is registered under clinical trial identifier NCT00915278. Target conditions include Advanced Non-Hematologic Malignancies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00915278 | Phase 1 | Terminated |
Competing Products
20 competing products in Advanced Non-Hematologic Malignancies